Use of tigit immunoadhesins in the preparation of an angiogenesis modulating product

By constructing a TIGIT immunoadhesin containing the LALA-PG mutant, the research gaps in TIGIT immunoadhesin regarding tumor immunity and angiogenesis were addressed, achieving the effects of enhancing immune cell killing of tumor cells and promoting angiogenesis, and applying it to the treatment of various tumors and vascular injury-related diseases.

CN115708865BActive Publication Date: 2026-11-10PHARCHOICE THERAPEUTICS INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202211361199.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-08-25
Filing Date
2020-09-22
Publication Date
2026-11-10
Estimated Expiration
2040-09-22

AI Technical Summary

Technical Problem

There is limited research on TIGIT immunoadhesins, which are formed by further genetic engineering of TIGIT proteins, and their applications in tumor immunity and angiogenesis have not been fully explored.

Method used

By constructing TIGIT immunoadhesins containing the domains of the natural TIGIT protein or functional variants thereof, particularly those containing the LALA-PG mutant to remove the Fc domain and enhance immunoglobulin activity, reagents can be prepared to enhance the killing of tumor cells by immune cells and regulate angiogenesis.

Benefits of technology

It significantly enhances the killing ability of immune cells against tumor cells, improves the immunosuppressive microenvironment of tumor tissues, promotes angiogenesis and vascular normalization, improves tissue blood supply, and reduces hypoxia. It can be applied to the treatment of various tumors and vascular injury-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003922634790000081
    Figure BDA0003922634790000081
  • Figure BDA0003922634790000091
    Figure BDA0003922634790000091
  • Figure BDA0003922634790000101
    Figure BDA0003922634790000101
Patent Text Reader

Abstract

The present application relates to the technical field of biological medicine engineering, and discloses a new use of TIGIT immunoadhesin in preparation of a product for regulating angiogenesis, wherein through experimental verification, the TIGIT immunoadhesin can improve the hypoxic condition of tumor tissue, increase blood supply, change the tumor growth environment, and thus hammer tumor cells. On the other hand, the TIGIT immunoadhesin can stimulate angiogenesis and enhance the healing of new tissues, thereby providing a certain direction for the treatment of vascular injury diseases and expanding the clinical application prospect and range of the TIGIT immunoadhesin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This case is a divisional application of application number 202011000490.7, filed on September 22, 2020, entitled "Application of TIGIT Immunoadhesin in Products Regulating Tumor Immunity and Angiogenesis". The domestic priority number of the parent application is 202010862713.4, with a priority date of August 25, 2020. Technical Field

[0002] This invention relates to the field of biomedical engineering technology, specifically to the application of TIGIT immunoadhesive in products that regulate tumor immunity and angiogenesis. Background Technology

[0003] TIGIT protein (UniProtKB ID: Q495A1) is a member of the poliovirus receptor (PVR) / Nectin family. It consists of an extracellular immunoglobulin variable region (IgV) domain, a type 1 transmembrane domain, and an intracellular domain with a classical immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoglobulin tyrosine tail (ITT) motif. It can be constructed into TIGIT immunoadhesins using immunoglobulin Fc fusion technology familiar to those skilled in the art.

[0004] TIGIT protein has a wide range of applications. Based on the research results, the applicant has filed two patent applications: Invention patent CN109206523A discloses the preparation of TIGIT immunoadhesin and its use in autoimmune diseases; Invention patent CN110669139A discloses the use of TIGIT immunoadhesin in regulating maternal-fetal immune tolerance.

[0005] The tumor immune cycle refers to the process by which an immune response is developed in an appropriate manner to kill cancer cells. In short, dendritic cells acquire antigens from dead cancer cells, then enter lymph nodes to activate T cells. The activated T cells leave the lymph nodes and enter the circulatory system, infiltrating the tumor microenvironment through blood vessel walls. The T cells recognize and kill tumor cells via specific receptors, and the cycle continues. In tumor immunity research, there has been considerable focus on the TIGIT protein itself, while research on the further genetic engineering of TIGIT protein to form TIGIT immunoadhesins is relatively limited. Summary of the Invention

[0006] During the research process, the applicant unexpectedly discovered that TIGIT immunoadhesive has unexpected technical effects in enhancing the killing of tumor cells by immune cells and promoting the regulation of angiogenesis.

[0007] The TIGIT immunoadhesive described in this invention refers to a domain of the natural TIGIT protein that has the ability to bind its natural ligand, or an ex vivo domain of the TIGIT protein, or a functional variant or fragment thereof. TIGIT adhesins have been described in detail in the background art documents and are well known to those skilled in the art, so they will not be described again here.

[0008] In some embodiments of the present invention, the TIGIT immunoadhesin Fc domain of the present invention further includes the LALA-PG mutant to remove the potential immunoglobulin activity of its Fc domain.

[0009] In a first aspect, the present invention provides the use of TIGIT immunoadhesive in the preparation of agents that enhance the immune system and immune cells to clear tumors or agents that regulate angiogenesis.

[0010] Specifically, the uses of TIGIT immunoadhesin described in this invention include: (1) enhancing the killing of tumor cells by immune cells, increasing the number of immune cells infiltrating tumor tissues, enhancing the recognition of tumor cells by immune cells, reducing the activity of immunosuppressive signals in tumor tissues, reducing epithelial-mesenchymal transition of tumor cells mediated by immune cell pressure, and sensitizing the tumor clearance effect mediated by immune checkpoint inhibitors. (2) promoting angiogenesis and vascular normalization, including recruiting vascular support cells, normalizing vascular networks, improving tissue blood supply, reducing tissue hypoxia, and reducing tissue damage, mainly reflected in promoting the proliferation, migration, and lumen formation ability of vascular endothelial cells.

[0011] The tumors referred to in this invention include solid tumors such as adenocarcinoma, leukemia, lymphoma, melanoma, and sarcoma. The sources of tumor tissue include, but are not limited to, the adrenal glands, gallbladder, bone, bone marrow, brain, breast, bile ducts, gastrointestinal tract, heart, kidneys, liver, lungs, muscles, ovaries, pancreas, parathyroid glands, penis, prostate, skin, salivary glands, spleen, testes, thymus, thyroid gland, and uterus. In addition to the aforementioned solid tumors, it can also be used for tumors of the central nervous system such as gliomas and astrocytomas; furthermore, it can be used for ocular tumors including basal cell carcinoma, squamous cell carcinoma, and melanoma; endocrine gland tumors; neuroendocrine system tumors; gastrointestinal and pancreatic endocrine system tumors; reproductive system tumors; hematologic malignancies; and head and neck tumors. These will not be listed exhaustively here.

[0012] The ability of TIGIT immunoadhesive to regulate angiogenesis enables the applications of TIGIT immunoadhesive disclosed in this article to include a variety of clinical diseases or conditions where promoting angiogenesis is desired. These conditions include promoting angiogenesis in regenerating tissues, ischemic limb diseases, endometrial microangiogenesis, promoting decidual microangiogenesis, cerebral ischemia, stimulation of hair growth, erectile dysfunction, arteriosclerosis, and vascular inflammatory necrosis.

[0013] In some embodiments of the invention, the clinical conditions for which angiogenesis is desired include stroke, macular degeneration, macular edema, lymphedema, blood-retinal barrier disruption, blood-brain barrier disruption, bacterial-induced vascular injury regeneration, particularly including vascular damage due to microvascular lesions during lung injury, kidney injury, renal fibrosis, stroke, vascular dementia, macular degeneration, and diabetic complications (e.g., in the kidneys, eyes, skin, and / or limbs).

[0014] Because the TIGIT immunoadhesive disclosed in this invention has the ability to stimulate angiogenesis, it can be further used in the preparation of products that enhance wound healing. This can be demonstrated, for example, by accelerated wound closure time compared to wound healing without the TIGIT immunoadhesive, increased granulation tissue at the wound site compared to untreated wounds, and / or enhanced neovascularization of the wound compared to untreated wounds.

[0015] In one embodiment, the method or use for stimulating wound healing is used to treat diabetic ulcers. In other embodiments, the method or use for stimulating wound healing can be used in a variety of clinical conditions involving trauma, including but not limited to pressure ulcers, pressure sores, surgical incisions, traumatic tissue injuries, burns, and tissue transplants.

[0016] In one implementation, the clinical condition for which angiogenesis is desired also includes normalizing blood vessels in tumor tissue to improve tumor hypoxia and reduce the risk of metastasis.

[0017] Therefore, in a second aspect, the present invention provides the use of agents that enhance the immune system and immune cells to clear tumors or agents that regulate angiogenesis in the preparation of antitumor drugs.

[0018] A third aspect of the present invention provides an enhancer or angiogenesis regulator that promotes the clearance of tumors by the immune system and immune cells, characterized in that it comprises TIGIT immunoadhesin, a nucleotide encoding thereon or a recombinant expression vector thereof as the sole active ingredient, and further comprises a pharmaceutically acceptable carrier.

[0019] The polynucleotide encoding TIGIT immunoadhesive can be in the form of RNA or DNA, including cDNA and synthetic DNA, and can be double-stranded or single-stranded. The coding sequence of the protein of the present invention can vary due to redundancy or degeneracy of the genetic code.

[0020] The polynucleotide encoding the TIGIT immunoadhesive of the present invention may include: a protein-coding sequence only; a protein-coding sequence and additional coding sequences (such as leader or secretory sequences or preprotein sequences); and a protein-coding sequence and non-coding sequences (such as introns or non-coding sequences at the 5' and / or 3' ends of the protein-coding sequence). Therefore, the term "protein-coding polynucleotide" encompasses not only polynucleotides that may include the protein-coding sequence but also polynucleotides that include additional coding and / or non-coding sequences.

[0021] A fourth aspect of the present invention provides an antitumor pharmaceutical composition. The composition comprises the TIGIT immunoadhesive disclosed herein and at least one immune checkpoint inhibitor, and further comprises a medically acceptable drug carrier. In certain specific embodiments of the present invention, the immune checkpoint inhibitor comprises a PD1 inhibitor, a PD-L1 inhibitor, and / or a CTLA4 inhibitor.

[0022] The TIGIT immunoadhesive of the present invention, together with other combined components and pharmaceutically acceptable excipients, forms a pharmaceutical formulation composition that provides more stable therapeutic efficacy. These formulations ensure the conformational integrity of the amino acid core sequence of the TIGIT immunoadhesive disclosed in this invention, while also protecting the multifunctional groups of the protein from degradation (including but not limited to aggregation, deamination, or oxidation).

[0023] Under normal circumstances, liquid formulations can be stored stably at 2℃-8℃ for at least one year, while lyophilized formulations remain stable at 30℃ for at least six months. The formulations can be commonly used in the pharmaceutical industry, such as suspensions, injections, or lyophilized formulations, with injections or lyophilized formulations being preferred.

[0024] For the aqueous or lyophilized formulations of the TIGIT immunoadhesive disclosed in this invention, pharmaceutically acceptable excipients include one or a combination of surfactants, solution stabilizers, isotonic adjusters, and buffers. Surfactants include nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters (Tween 20 or 80); poloxamer (e.g., poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; tetradecyl, linoleic, or octadecyl sarcosine; Pluronics; MONAQUAT™, etc., and their addition should minimize the granulation tendency of the bifunctional, bispecific antibody protein. Solution stabilizers can be sugars, including reducing and non-reducing sugars; amino acids, including monosodium glutamate or histidine; alcohols, including one or a combination of triols, higher sugar alcohols, propylene glycol, and polyethylene glycol, and the amount of solution stabilizer added should be such that the final formulation remains stable within a time considered stable by those skilled in the art. Isotonic adjusters can be one of sodium chloride or mannitol. Buffers can be one of TRIS, histidine buffer, or phosphate buffer.

[0025] The above-mentioned formulation is a composition containing TIGIT immunoadhesive, which has shown significant anti-tumor effects and angiogenesis-stimulating effects after administration to animals, including humans. Specifically, it is effective in treating tumors or vascular damage-related conditions and can be used as a drug for these conditions.

[0026] In this invention, when TIGIT immunoadhesive and its compositions are administered to animals, including humans, the dosage varies depending on the patient's age and weight, disease characteristics and severity, and route of administration. The dosage should be determined with reference to animal experimental results and various other factors, but the total dosage should not exceed a certain range. Specifically, the intravenous injection dose is 1–1800 mg / day.

[0027] The beneficial protections and effects of this invention are as follows:

[0028] This invention discloses a novel application of TIGIT immunoadhesive in products that regulate tumor immunity and angiogenesis. Experimental verification shows that TIGIT immunoadhesive can effectively enhance the killing and recognition of tumor cells by immune cells; enhance the growth inhibition of tumor tissues by immune cells; improve immunosuppressive signals within tumor tissues, disrupting the tumor immunosuppressive microenvironment; and simultaneously improve tumor tissue hypoxia, increase blood supply, and alter the tumor growth environment, thus attacking tumor cells from two aspects. Furthermore, TIGIT immunoadhesive can stimulate angiogenesis and enhance the healing of new tissue, providing a direction for the treatment of vascular injury diseases and expanding the clinical application prospects and scope of TIGIT immunoadhesive. Detailed Implementation

[0029] The following examples and experimental cases further illustrate the present invention and should not be construed as limiting the invention. The examples do not include detailed descriptions of conventional methods, such as those used for constructing vectors and plasmids, inserting genes encoding proteins into such vectors and plasmids, or introducing plasmids into host cells. Such methods are well known to those skilled in the art and have been described in numerous publications, including Sambrook, J., Fritsch, E.F. and Maniais, T. (1989) Molecular Cloning: A Laboratory Manual, 2 nd edition, Cold spring Harbor Laboratory Press.

[0030] Example 1: Preparation of TIGIT Immunoadhesive

[0031] According to the description in patent document CN110669139A, two immunoadhesins, TIGIT-Fc-wt and TIGIT-FC-LALA-PG, were prepared respectively.

[0032] Example 2: TIGIT Immunoadhesin-Mediated Immune Cell Killing of Tumor Cells

[0033] Following the method described in the literature [Fu W, et al. Nature communications, 2019, 10(1): 1-12.], the killing effect of peripheral blood mononuclear cells (PBMCs) on breast cancer cell line SK-BR-3, lung cancer cell line HCC827, gastric cancer cell line N87, and ovarian cancer cell line SK-OV-3 in the presence of TIGIT immunoadhesive was evaluated. The effector cell to target cell ratio was 10:1, the drug concentration was 1 μg / ml, control IgG was used as a negative control, and no drug was added as a blank control. The cell killing rate was the final cell signal / blank control cell signal of each treatment group. The results are shown in Tables 1-4.

[0034] Table 1. Killing effect of PBMC on SK-BR-3

[0035] Group Cell killing rate (% blank control) SD P-value vs. control IgG Control IgG 10.25 2.45 TIGIT-Fc-wt 72.91 4.37 P<0.01 TIGIT-FC-LALA-PG 45.65 3.19 P<0.01

[0036] Table 2 shows the toxic effects of PBMC on HCC827.

[0037] Group Cell killing rate (% blank control) SD P-value vs. control IgG Control IgG 10.30 3.21 TIGIT-Fc-wt 66.88 14.44 P<0.01 TIGIT-FC-LALA-PG 48.67 10.80 P<0.01

[0038] Table 3. Killing effect of PBMC on N87

[0039] Group Cell killing rate (% blank control) SD P-value vs. control IgG Control IgG 12.10 2.98 TIGIT-Fc-wt 79.40 11.96 P<0.01 TIGIT-FC-LALA-PG 52.56 6.64 P<0.01

[0040] Table 4 shows the lethal effect of PBMCs on N87.

[0041] Group Cell killing rate (% blank control) SD P-value vs. control IgG Control IgG 11.99 2.36 TIGIT-Fc-wt 75.09 17.50 P<0.01 TIGIT-FC-LALA-PG 47.19 11.80 P<0.01

[0042] These experiments show that the TIGIT immunoadhesive described in this invention significantly enhances the killing activity of immune cells against tumor cells.

[0043] Furthermore, following the method described in the literature [Fu W, et al. Nature communications, 2019, 10(1): 1-12.], a model of the above-mentioned tumor cell line in immunodeficient mice was established, and the killing effect of PBMCs on tumor cells in the in vivo model was evaluated. The tumor growth inhibition rate (TGI) was calculated, and the methods for immune cell injection and tumor volume calculation in the mouse model were all based on existing literature. Seven mice were used in each group, and the mice were treated with the drug once a week for three consecutive weeks, with 40 mg / kg injected via the tail vein. The control IgG was used as a negative control, and the saline group was used as a blank control. The results are shown in Tables 5-8.

[0044] Table 5 Evaluation of the SK-BR-3 mouse model of tumor bearing and immune cell activity

[0045] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 7.90 1.19 TIGIT-Fc-wt 78.97 23.44 P<0.01 TIGIT-FC-LALA-PG 64.16 14.67 P<0.01

[0046] Table 6 Evaluation of the HCC827 mouse model of tumor bearing and immune cell action

[0047] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 4.71 2.29 TIGIT-Fc-wt 67.07 5.70 P<0.01 TIGIT-FC-LALA-PG 49.85 10.35 P<0.01

[0048] Table 7 Evaluation of the N87 mouse model of tumor bearing and immune cell action

[0049] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 7.93 3.82 TIGIT-Fc-wt 61.79 12.55 P<0.01 TIGIT-FC-LALA-PG 67.14 7.77 P<0.01

[0050] Table 8 Evaluation of the SK-OV-3 mouse model of tumor bearing and immune cell activity

[0051] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 6.09 3.20 TIGIT-Fc-wt 89.64 16.33 P<0.01 TIGIT-FC-LALA-PG 71.80 19.90 P<0.01

[0052] The above experiments show that, in an in vivo model, the TIGIT immunoadhesive described in this invention effectively enhances the inhibition of tumor tissue growth by immune cells.

[0053] Furthermore, the tumor tissues obtained after the mouse model experiments were isolated, and the expression of PDL1 in each tumor tissue was detected. The isolation of tumor tissues and the detection of gene expression within the tissues were described in references [Hu S, et al. Science Translational Medicine, 2017, 9(380); Yen WC, et al. Clinical Cancer Research, 2015, 21(9):2084-2095.]. The results are shown in Tables 9-12.

[0054] Table 9. Relative expression of PDL1 protein in tissues after the completion of the SK-BR-3 mouse tumor-bearing model.

[0055] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 110.47 21.23 TIGIT-Fc-wt 57.27 18.20 P<0.01 TIGIT-FC-LALA-PG 41.18 19.24 P<0.01

[0056] Table 10. Relative expression of PDL1 protein in tissues after the HCC827 mouse tumor-bearing model ends.

[0057] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 124.05 36.89 TIGIT-Fc-wt 9.94 3.11 P<0.01 TIGIT-FC-LALA-PG 13.28 1.77 P<0.01

[0058] Table 11 Relative expression of PDL1 protein in tissues after the N87 mouse tumor-bearing model was completed.

[0059] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 119.23 13.60 TIGIT-Fc-wt 47.78 10.36 P<0.01 TIGIT-FC-LALA-PG 29.20 4.80 P<0.01

[0060] Table 12. Relative expression of PDL1 protein in tissues after the completion of the SK-OV-3 mouse tumor-bearing model.

[0061] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 116.27 18.15 TIGIT-Fc-wt 38.24 11.59 P<0.01 TIGIT-FC-LALA-PG 10.68 2.06 P<0.01

[0062] These experiments demonstrate that the TIGIT immunoadhesive described in this invention effectively improves intra-tissue immunosuppressive signals, disrupts the tumor immunosuppressive microenvironment, and facilitates the function of immune cells in tumor tissues.

[0063] Furthermore, the expression levels of E-cadherin and Vimentin in the tissue were detected. These two markers are epithelial-mesenchymal transition markers. The results are shown in Tables 13-20.

[0064] Table 13. Relative expression of E-cadherin protein in tissues after the completion of the SK-BR-3 mouse tumor-bearing model.

[0065] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 100.34 7.59 TIGIT-Fc-wt 213.21 22.79 P<0.01 TIGIT-FC-LALA-PG 195.88 7.91 P<0.01

[0066] Table 14. Relative expression of Vimentin protein in tissues after the completion of the SK-BR-3 mouse tumor-bearing model.

[0067] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 105.71 13.13 TIGIT-Fc-wt 65.89 14.62 P<0.01 TIGIT-FC-LALA-PG 63.60 8.28 P<0.01

[0068] Table 15. Relative expression of E-cadherin protein in tissues after the HCC827 mouse tumor-bearing model was completed.

[0069] Group Relative expression (% blank control) SD P-value vs. control IgG Control IgG 108.52 33.08 TIGIT-Fc-wt 173.79 44.09 P<0.01 TIGIT-FC-LALA-PG 199.39 17.32 P<0.01

[0070] Table 16. Relative expression of Vimentin protein in tissues after the completion of the SK-BR-3 mouse tumor-bearing model.

[0071]

[0072]

[0073] Table 17 Relative expression of E-cadherin protein in tissues after the N87 mouse tumor-bearing model was completed.

[0074] Group Sex pair expression (% blank control) SD P-value vs. control IgG Control IgG 110.82 45.91 TIGIT-Fc-wt 204.62 18.22 P<0.01 TIGIT-FC-LALA-PG 248.22 20.95 P<0.01

[0075] Table 18 Relative expression of Vimentin protein in tissues after the N87 mouse tumor-bearing model was completed.

[0076] Group Sex pair expression (% blank control) SD P-value vs. control IgG Control IgG 104.88 28.88 TIGIT-Fc-wt 47.10 11.68 P<0.01 TIGIT-FC-LALA-PG 66.65 10.29 P<0.01

[0077] Table 19. Relative expression of E-cadherin protein in tissues after the completion of the SK-OV-3 mouse tumor-bearing model.

[0078] Group Sex pair expression (% blank control) SD P-value vs. control IgG Control IgG 101.18 29.62 TIGIT-Fc-wt 173.51 44.16 P<0.01 TIGIT-FC-LALA-PG 190.65 76.82 P<0.01

[0079] Table 20. Relative expression of Vimentin protein in tissues after the completion of the SK-OV-3 mouse tumor-bearing model.

[0080] Group Sex pair expression (% blank control) SD P-value vs. control IgG Control IgG 106.71 33.64 TIGIT-Fc-wt 44.29 4.15 P<0.01 TIGIT-FC-LALA-PG 22.41 10.19 P<0.01

[0081] These experiments demonstrate that the TIGIT immunoadhesive described in this invention significantly enhances the expression of E-cadherin in tumor tissue and reduces the expression level of Vimentin protein, thereby significantly inhibiting epithelial-mesenchymal transition mediated by immune cells and treatment and reducing the risk of tumor metastasis.

[0082] Example 3: Effects of TIGIT Immunoadhesin on Vascular and Microcirculatory Functions in Tumor Tissue

[0083] The tumor tissues in the above examples were further subjected to histochemical analysis to detect the perfusion vessels within the tissues. Simultaneously, the tissue hypoxia level was detected using immunohistochemistry, following the same method as described in the literature [Hu S, et al. Science Translational Medicine, 2017, 9(380); Yen WC, et al. Clinical Cancer Research, 2015, 21(9):2084-2095.]. The results are shown in Tables 21-24:

[0084] Table 21. Tissue perfusion vascularity after the completion of the SK-BR-3 mouse tumor-bearing model.

[0085]

[0086] Table 22. Tissue hypoxia after the completion of the SK-BR-3 mouse tumor-bearing model.

[0087] Group Hypoxia signals (% blank control) SD P-value vs. control IgG Control IgG 105.31 27.35 TIGIT-Fc-wt 10.60 3.20 P<0.01 TIGIT-FC-LALA-PG 8.17 6.06 P<0.01

[0088] Table 23. Tissue perfusion vascularity after the HCC827 mouse tumor-bearing model was completed.

[0089]

[0090] Table 24. Tissue hypoxia after the HCC827 mouse tumor-bearing model was completed.

[0091] Group Hypoxia signals (% blank control) SD P-value vs. control IgG Control IgG 112.61 35.26 TIGIT-Fc-wt 7.90 2.52 P<0.01 TIGIT-FC-LALA-PG 8.72 1.88 P<0.01

[0092] These experiments demonstrate that the TIGIT immunoadhesive described in this invention significantly enhances blood vessel perfusion in tumor tissue, stimulates angiogenesis in tumor tissue, and reduces tissue hypoxia.

[0093] Example 4: Effects of TIGIT Immunoadhesin on a Mouse Allogeneic Transplantation Model

[0094] A mouse model under normal immune status was established using the mouse colon cancer cell line MC38. The model establishment is referenced in [Juneja VR, et al. Journal of Experimental Medicine, 2017, 214(4):895-904.]. Mice were grouped and administered drugs according to the method in Example 2, and treated with immunoadhesin. Human immune cells were not required to assess immune cell status at this time. TGI was calculated, and the results are shown in Table 25.

[0095] Table 25 Evaluation of the MC38 mouse tumor-bearing animal model

[0096] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 3.94 5.91 TIGIT-Fc-wt 100 - P<0.01 TIGIT-FC-LALA-PG 100 - P<0.01

[0097] The results showed that all tumors in the TIGIT immunoadhesive treatment group were cleared.

[0098] To further assess the condition within the tissues and reduce treatment time, the mice were euthanized one week after treatment, at which point the TGI was shown in Table 26.

[0099] Table 26 Evaluation of Shortened Treatment Time in MC38 Tumor-Bearing Mouse Model

[0100] Group TGI (% blank control) SD P-value vs. control IgG Control IgG 9.13 4.31 TIGIT-Fc-wt 76.55 8.75 P<0.01 TIGIT-FC-LALA-PG 65.91 16.69 P<0.01

[0101] At this point, tumor tissue was separated according to the method described in the above embodiment, and the level of CD8 lymphocyte infiltration in the tissue was detected by immunohistochemistry. The method is referenced in [Demotte N, et al. Cancer research, 2010, 70(19): 7476-7488.], and the results are shown in Table 27.

[0102] Table 27 Lymphocyte infiltration in MC38 tissue

[0103]

[0104] The experiment showed that TIGIT immunoadhesin can effectively increase the infiltration of lymphocytes in tumor tissue.

[0105] Furthermore, the vascular perfusion and hypoxia in the tumor tissue were assessed according to the methods in the above embodiments, and the results are shown in Tables 28-29.

[0106] Table 28 shows the tissue perfusion vascularity after the completion of the MC38 mouse tumor-bearing model.

[0107]

[0108] Table 29. Tissue hypoxia after the MC38 mouse tumor-bearing model was completed.

[0109] Group Hypoxia signals (% blank control) SD P-value vs. control IgG Control IgG 105.84 23.45 TIGIT-Fc-wt 7.84 3.71 P<0.01 TIGIT-FC-LALA-PG 9.74 3.32 P<0.01

[0110] These experiments demonstrate that the TIGIT immunoadhesive described in this invention significantly enhances blood vessel perfusion in tumor tissue, stimulates angiogenesis in tumor tissue, and reduces tissue hypoxia.

[0111] Example 5: Effects of TIGIT Immunoadhesin on Vascular Endothelial Cells

[0112] The effects of TIGIT immunoadhesin on HUVEC vascular endothelial cells were evaluated according to the method described in patent literature (CN 102884073 A). The dosage of immunoadhesin was 1 μg / ml. VEGF was used as a positive control. The results are shown in Tables 30-32.

[0113] Table 30 Effects of TIGIT Immunoadhesin on Vascular Endothelial Cell Proliferation

[0114] Group Cell proliferation (% blank control) SD P-value vs. control IgG Control IgG 91.29 10.54 VEGF 159.96 15.85 P<0.01 TIGIT-Fc-wt 219.27 37.63 P<0.01 TIGIT-FC-LALA-PG 169.15 31.89 P<0.01

[0115] Table 31 Effects of TIGIT Immunoadhesin on Vascular Endothelial Cell Migration

[0116] Group Cell proliferation (% blank control) SD P-value vs. control IgG Control IgG 100.76 22.84 VEGF 195.45 12.07 P<0.01 TIGIT-Fc-wt 173.91 38.20 P<0.01 TIGIT-FC-LALA-PG 179.26 32.39 P<0.01

[0117] Table 32 Effects of TIGIT Immunoadhesin on Vascular Endothelial Cell Lumen Formation

[0118] Group Cellular lumen (lumens per field of view) SD P-value vs. control IgG Blank control 1.750 0.500 Control IgG 2.000 0.816 VEGF 14.250 2.217 P<0.01 TIGIT-Fc-wt 13.250 1.893 P<0.01 TIGIT-FC-LALA-PG 15.750 2.986 P<0.01

[0119] These experiments show that the TIGIT immunoadhesin disclosed in this invention has the function of promoting the proliferation, migration, and lumen formation of vascular endothelial cells.

[0120] Further, following the method described in reference (CN 102884073 A), the in vivo angiogenesis capacity of the matrix gel plug was assessed using a C57 mouse in vivo model. The dosage of both the control drug and the immunoadhesive was 1 mg, and the volume of the drug-matrix mixture was 600 μl. The results are shown in Table 33.

[0121] Table 33 Effects of TIGIT Immunoadhesin on Angiogenesis in an In Vivo Model

[0122]

[0123]

[0124] The experiment shows that the TIGIT immunoadhesive disclosed in this invention has the effect of promoting angiogenesis in vivo.

[0125] Example 6: Combined application of TIGIT immunoadhesive

[0126] To further clarify the immunomodulatory effect of TIGIT immunoadhesin, a combination of anti-PD-L1 antibody, anti-PD-1 antibody, and anti-CTLA4 antibody was used in an MC38 tumor model. All antibody drugs were administered as a single dose of 10 mg / kg, following the method described in Example 2. The combined administration dose was 5 mg / ml of each of the two drugs, n = 10. The experimental methods for controlling the antibody and tumor clearance can be found in the references [Woo SR, Turnis ME, Goldberg MV, et al.. Cancerresearch, 2012, 72(4):917-927.; Dixon KO, Schorer M, Nevin J, et al.. The Journal of Immunology, 2018, 200(8):3000-3007.]

[0127] Table 34 Tumor clearance rate in mice

[0128] Group Tumor clearance rate (%) Control IgG 0 TIGIT-Fc-wt 30 TIGIT-FC-LALA-PG 20 Anti-PD-1 20 Anti-PD-L1 20 Anti-CTLA4 30 TIGIT-Fc-wt+Anti-PD-1 90 TIGIT-Fc-wt+Anti-PD-L1 100 TIGIT-Fc-wt+Anti-CTLA4 90

[0129] The experiment shows that the TIGIT immunoadhesive disclosed in this invention can mediate the clearance of some tumor tissues, and its anti-tumor effect can be significantly enhanced when used in combination with anti-PD-L1 antibody, anti-PD-1 antibody and anti-CTLA4 antibody.

[0130] Furthermore, the tumor model was re-established and the experiment was repeated. Before the tumors regressed, PD-L1 expression was detected in tumor tissues of each treatment group. The detection method can be found in the reference [Jiao S, Xia W, Yamaguchi H, et al. Clinical Cancer Research, 2017, 23(14):3711-3720].

[0131] Table 35. PD-L1 expression levels in each group of tissues

[0132]

[0133] The experiment shows that the TIGIT immunoadhesin disclosed in this invention, when used in combination with PD-1 / PD-L1 inhibitors in an immunocompetent mouse tumor model, reduces the loss of intra-tissue antigens caused by PD-1 / PD-L1 inhibitors and can enhance the anti-tumor effect of PD-L1 / PD-1 signaling pathway inhibitors.

[0134] Example 7: The effect of TIGIT immunoadhesin on angiogenesis in a pathological model

[0135] (1) Effects on promoting angiogenesis and improving ischemic limb recovery in diabetic mice with limb ischemia

[0136] The disease model was established according to patent literature (CN 103260628 A). After 4 weeks of drug administration, the results were assessed. The dosage was 40 mg / kg intravenously once weekly. Each group had n=6. Blood flow was assessed according to the method described in the literature. The results are shown in Table 34.

[0137] Table 36 Effects on angiogenesis in in vivo models

[0138]

[0139] Further physiological examinations were performed according to the methods described in the literature, and the results are shown in Table 35:

[0140] Table 37 Effects of Ischemic Hindlimb Recovery

[0141] Group Fraction SD P-value vs. control IgG Control IgG 2.833 0.408 TIGIT-Fc-wt 13.167 0.408 P<0.01 TIGIT-FC-LALA-PG 13.500 0.548 P<0.01

[0142] The animals were euthanized, and the capillary density of the leg skin was assessed according to the method described in the patent literature. The results are shown in Table 36.

[0143] Table 38 Tissue Capillaries

[0144]

[0145] These experiments show that the TIGIT immunoadhesive disclosed in this invention effectively enhances local blood flow in diabetic limb ischemia mice and effectively reduces complications.

[0146] (2) Effects on angiogenesis and healing after endometrial injury

[0147] Furthermore, a mouse endometrial injury model was established according to the method described in patent document CN 110721196 A. After successful modeling, the mice were treated with the TIGIT immunoadhesive disclosed in this invention for 3 weeks. The mouse tissues were then separated, and the endometrial capillary density was assessed using an image analyzer (Xu Qing, et al. Journal of Capital Medical University (2): 104-107.). The results are shown in Table 37.

[0148] Table 39 Tissue Capillaries

[0149]

[0150] A mouse model of endometrial injury and thickened pregnancy was further established according to the method described in patent document CN 110721196 A. The mouse pregnancy tissue was then assessed, and the tissue capillary density and final pregnancy outcome are shown in Tables 38-39.

[0151] Table 40 Deciduous Spiral Artery Vessels

[0152] Group Vascular density (% blank control) SD P-value vs. control IgG Control IgG 112.92 20.64 TIGIT-Fc-wt 1236.48 136.27 P<0.01 TIGIT-FC-LALA-PG 1143.29 123.77 P<0.01

[0153] Table 41 Pregnancy rates in each group

[0154] Group Pregnancy rate P-value vs. control IgG normal mice 100% Model group 20% Control IgG 10% TIGIT-Fc-wt 90% P<0.01 TIGIT-FC-LALA-PG 80% P<0.01

[0155] These results show that the TIGIT immunoadhesive disclosed in this invention effectively reduces endometrial damage, enhances endometrial microvascular formation, increases decidual spiral artery density, and improves pregnancy outcomes.

[0156] (3) Effects on corneal injury models

[0157] A rat model of corneal alkali burn was established according to the method described in patent document CN 106265682 A. The administration route was intravenous injection of 50 mg / kg of the described immunoadhesin and control drug daily. The corneal damage area was assessed 7 days post-surgery using the method described in the patent document. The results are shown in Table 40.

[0158] Table 42 Corneal Damage Area

[0159] Group <![CDATA[Lesion area (mm 2 )]]> SD P-value vs. control IgG Model 1.26 0.36 Control IgG 1.51 0.26 TIGIT-Fc-wt 0.37 0.08 P<0.01 TIGIT-FC-LALA-PG 0.29 0.12 P<0.01

[0160] The experiment shows that the TIGIT immunoadhesive disclosed in this invention effectively reduces the area of ​​corneal damage and effectively improves tissue healing.

[0161] (4) Impact on cardiac injury models

[0162] A rat model of heart failure was established by ligation of the left anterior descending artery according to the method described in the literature [Li T, et al..The FASEB Journal,2019,33(6):7467-7478.]. Immunohistoin was administered twice weekly via tail vein injection at a dose of 50 mg / kg. After 4 weeks, cardiac tissue was separated for pathological examination, and Masson staining was performed to assess the infarct area. The results are shown in Table 41:

[0163] Table 43 Infarct Area

[0164] Group Damage area (%) (blank control) SD P-value vs. control IgG Control IgG 121.78 39.19 TIGIT-Fc-wt 55.73 11.66 P<0.01 TIGIT-FC-LALA-PG 60.39 16.50 P<0.01

[0165] Simultaneously, histochemical analysis of tissue hypoxia was performed, and the results are shown in Table 42:

[0166] Table 44 Myocardial tissue hypoxia

[0167] Group Hypoxia signals (% blank control) SD P-value vs. control IgG Control IgG 118.83 26.31 TIGIT-Fc-wt 24.68 10.79 P<0.01 TIGIT-FC-LALA-PG 9.47 2.35 P<0.01

[0168] The experiment shows that the TIGIT immunoadhesive disclosed in this invention effectively reduces tissue damage after myocardial infarction and alleviates tissue hypoxia.

[0169] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. The use of TIGIT immunoadhesive in the preparation of drugs for treating and repairing vascular damage, characterized in that, The drug for treating vascular damage repair is a drug for improving ischemic limbs in diabetic patients, and the TIGIT immunoadhesive is TIGIT-Fc-wt or TIGIT-FC-LALA-PG immunoadhesive as described in patent document CN110669139A.

2. The use according to claim 1, characterized in that: in, The drug has TIGIT immunoadhesive, the nucleotide encoding it, or a recombinant expression vector loaded with the nucleotide as its sole active ingredient, and also includes pharmaceutically acceptable vectors.

Citation Information

Patent Citations

  • Peptides for promoting angiogenesis and a use thereof

    CN102884073A

  • Use of hyaluronan for promoting angiogenesis

    CN103260628A

  • Application of celastrol to preparing eye drop preparation for inhibiting alkali burn corneal neovascularization and promoting corneal alkali burn healing

    CN106265682A

  • TIGIT immunoadhesin and preparation method and use thereof

    CN109206523A

  • Application of decidua NK cells and decidua NK cell exosomes from cell subsets in preparing drugs and auxiliary therapeutic agents for treating diseases related to infertility

    CN110721196A